SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-23-086979
Filing Date
2023-11-14
Accepted
2023-11-14 16:20:39
Documents
73
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0923_unicycive.htm   iXBRL 10-Q 735085
2 CERTIFICATION f10q0923ex31-1_unicycive.htm EX-31.1 11232
3 CERTIFICATION f10q0923ex31-2_unicycive.htm EX-31.2 11229
4 CERTIFICATION f10q0923ex32-1_unicycive.htm EX-32.1 3769
5 CERTIFICATION f10q0923ex32-2_unicycive.htm EX-32.2 3672
  Complete submission text file 0001213900-23-086979.txt   5313253

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE uncy-20230930.xsd EX-101.SCH 61405
7 XBRL CALCULATION FILE uncy-20230930_cal.xml EX-101.CAL 31472
8 XBRL DEFINITION FILE uncy-20230930_def.xml EX-101.DEF 284747
9 XBRL LABEL FILE uncy-20230930_lab.xml EX-101.LAB 552495
10 XBRL PRESENTATION FILE uncy-20230930_pre.xml EX-101.PRE 305979
67 EXTRACTED XBRL INSTANCE DOCUMENT f10q0923_unicycive_htm.xml XML 592514
Mailing Address 4300 EL CAMINO REAL, SUITE 210 LOS ALTOS CA 94022
Business Address 4300 EL CAMINO REAL, SUITE 210 LOS ALTOS CA 94022 650-384-0642
Unicycive Therapeutics, Inc. (Filer) CIK: 0001766140 (see all company filings)

IRS No.: 813638692 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40582 | Film No.: 231406691
SIC: 2834 Pharmaceutical Preparations